A decade later, GMP problems cost Schering-Plough another $165 million
This article was originally published in The Gold Sheet
Executive Summary
Manufacturing problems at four facilities in the late 1990s continue to haunt Schering-Plough. The company paid $165 million last month to settle a related shareholder class action. The shareholders alleged that Schering had delayed disclosure of the severity of the GMP issues and the risk that FDA would respond by holding up approval of its allergy drug Clarinex, a successor to Claritin. FDA delayed the launch by a year ("The Gold Sheet," June 2002)
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.